OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center director Eight NCI-designated centers believe the top job is too big for one person

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.

May 08, 2026

Vol.52 No.18

Clinical Roundup

DYV800 topical therapy targets tumor acidity, preclinical study finds

A novel transdermal therapy designed to modulate tumor pH called DYV800 helped make tumors substantially less acidic, restore T-cell activity, slow tumor growth, and improve survival in preclinical studies, according to a study using animal models of bladder cancer conducted by Dyve Biosciences, in collaboration with Moffitt Cancer Center.

April 17, 2026

Vol.52 No.15

NCI

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

The National Cancer Advisory Board has established an ad hoc working group that will assess cancer centers as part of the designation process. The decision was approved unanimously with one abstention at the NCAB meeting March 17.

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

A research team at Oregon Health & Science University discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

January 09, 2026

Vol.52 No.1

In Brief

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

October 10, 2025

Vol.51 No.37

In Brief

Moffitt and Mainsail collaborate to bring $84M full-service hotel to Tampa

Moffitt Cancer Center and Tampa-based Mainsail Lodging & Development announced a partnership to bring a new 200-room, full-service hotel to Moffitt’s McKinley Campus. Expected to open in summer 2028, the hotel aims to enhance the experience of patients, families, visiting physicians and scientists, and the broader community.

September 26, 2025

Vol.51 No.35

OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center director

Eight NCI-designated centers believe the top job is too big for one person

YOU MAY BE INTERESTED IN

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

DYV800 topical therapy targets tumor acidity, preclinical study finds

A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Moffitt and Mainsail collaborate to bring $84M full-service hotel to Tampa

Renew today!

Subscriber content

Never miss an issue!

Login